Fate Therapeutics Inc. (FATE) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Fate Therapeutics Inc. (FATE:NASDAQ), powered by AI.

Current Price
$1.37
P/E Ratio
-0.8
Market Cap
156M
Sector
Healthcare
What is the Fate Therapeutics Inc. stock price forecast?

Fate Therapeutics Inc. is currently trading at $1.37. View real-time AI analysis on Alpha Lenz.

What is Fate Therapeutics Inc. insider trading activity?

View the latest insider trading data for Fate Therapeutics Inc. on Alpha Lenz.

What is Fate Therapeutics Inc.'s P/E ratio?

Fate Therapeutics Inc.'s P/E ratio is -0.8.

Fate Therapeutics Inc.

NASDAQ · FATE
$1.37
Ask about Fate Therapeutics Inc.'s future dividend policy...
Alpha Chat Insight

Fate Therapeutics Inc. trades at a P/E of -0.8 (undervalued) with modest ROE of -54.2%.

Ask for details

Company Overview

Fate Therapeutics Inc. operates within the biotechnology sector, specializing in the development of programmed cellular immunotherapies for cancer and immune disorders. The company's key focus lies in creating off-the-shelf cellular therapy candidates by using pluripotent stem cells combined with proprietary cell programming technology. This unique approach aims to generate a consistent and scalable source of cell-based therapies. Fate Therapeutics is at the forefront of innovation within its field, working on therapies that possess the potential to transform current treatment paradigms in oncology and immunology. As a significant player in the biotech arena, Fate collaborates with other industry leaders and research institutions to advance its product pipeline. Established in the early 2000s and headquartered in San Diego, California, the company is strategically positioned to address critical unmet medical needs, potentially impacting patients worldwide by offering novel therapeutic solutions in challenging medical domains. Its efforts underline the growing importance and potential of cellular therapies in modern medicine.

CEODr. Bahram Valamehr M.B.A., Ph.D.
SectorHealthcare
IndustryBiotechnology
Employees181

Company Statistics

FY 2024

Profile

$155.75MMarket Cap
$13.63MRevenue
0.00Shares Out
181Employees

Margins

N/AGross
-1193.30%EBITDA
-1434.52%Operating
-1366.46%Pre-Tax
-1366.46%Net

Valuation

-0.84P/E
0.49P/B
11.43EV/Sales
-1.26EV/EBITDA
-1.26P/FCF

Growth (CAGR)

-37.51%Rev 3Yr
5.00%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-39.34%ROA
-54.21%ROE
-41.30%ROIC

Financial Health

$36.06MCash & Cash Equivalents
$85.91MNet Debt
38.27%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Fate Therapeutics Inc. (ticker: FATE) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 181 employees. Market cap is $156M.

The current price is $1.37 with a P/E ratio of -0.84x and P/B of 0.49x.

ROE is -54.21% and operating margin is -1434.52%. Annual revenue is $14M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Fate Therapeutics Inc. (Healthcare) Stock Forecast & Analysis $1.37 | Alpha Lenz